CML ADVOCATES NETWORK

CML-CAB: Warsaw, Poland, 2018

Back to Overview

5th CML-CAB: Warsaw, Poland, 7-8 May 2018

On 7-8 May 2018, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its 5th meeting to discuss issues of major concern to the CML community. The meeting was made up of 3 sessions: Novartis, Pfizer, Incyte.

The following topics were discussed during the session with Novartis, 7th May 2018, 13:00-17:00:

  • ABL001 – Clinical Development Program Updates
  • Patient-Reported Outcomes
  • Precision Medicine –Novartis strategy in CML
  • TFR/CML educational materials
  • Novartis access program
  • Discussion and Next Steps

The following topics were discussed during the session with CML-CAB with Pfizer, 8th May 2018, 08:00-12:00:

  • Clinical and Medical Update
  • Use of Patient report outcomes and in Bosutinib’s clinical trial program
  • Patient and physician information on Bosutinib
  • Access to Bosutinib
  • Collaboration with Pfizer and challenges
  • Discussion and Next Steps

The following topics were discussed during the session with CML-CAB with Incyte 8th May 2018, 13:00-15:00:

  • Clinical update and R&D
  • Access to Ponatinib
  • The collaboration of Incyte with the CML patient community
  • Incyte’s CML Patient Support Program
  • Discussion and Next Steps